Background and aim Associations between pre-liver transplantation (pre-LT) BMI and post-LT survival are well described; however, there are few data assessing the associations between the commonly observed post-LT BMI changes and survival. We investigated the impact of early post-LT BMI change on post-LT patient and graft survival. Methods Using United Network for Organ Sharing data, we identified 2968 adult primary LT recipients who were not overweight pre-LT (BMI > 16 to ≤ 25 kg/m 2 ), and who had BMI recorded at 2 years post-LT. Delta BMI was defined as the BMI difference between pre-LT and 2 years post LT. Recipients were grouped into three categories: BMI gain (increase by > 1 BMI point), BMI loss (decrease by > 1 BMI point), and BMI stable (maintained BMI within 1 point). Associations between delta BMI and patient and graft survival were evaluated using Kaplan-Meier and multivariable Cox regression analyses. Results BMI gain was common (54%) and associated with significantly greater 5-year patient and graft survival (90 and 89%, respectively), compared with recipients who had either BMI loss (77 and 74%, respectively, P < 0.0001 for both) or were BMI stable (83%, P = 0.04 and 82%, P = 0.007, respectively). In multivariable analyses, increasing delta BMI was found to be inversely associated with risk for death and graft loss [hazard ratio 0.89 (95% confidence interval 0.86-0.91), P < 0.001; and hazard ratio 0.88 (95% confidence interval 0.86-0.91), P < 0.001, respectively]. Conclusion This study of a large national liver transplant database demonstrated that post-LT BMI gain was associated with better patient and graft survival, whereas BMI loss was associated with reduced patient and graft survival. Eur J Gastroenterol Hepatol 28:107-115
Introduction
Data from the Centers for Disease Control and Prevention suggest that more than 35% of the US adult population is obese [1] . Obesity is associated with increased mortality and was linked to significant morbidity including diabetes, cardiovascular disease, and chronic liver disease [2, 3] . The rise in prevalence of obesity in the general population has also had an impact on liver transplantation (LT), with more than 10% of new recipients having a BMI of 35 kg/m 2 or higher [4] .
Weight change post LT is commonly observed, especially weight gain [5] [6] [7] [8] [9] . An analysis of a well-characterized multicenter LT database demonstrated that during the first and second year post LT, the mean weight gain was 6 and 3 kg, respectively [6] . Subsequent to 2 years post LT, recipient weight did not change in a statistically or clinically significant manner. Pre-LT obesity was shown to be a risk factor for post-LT obesity, even after correcting for ascites weight [10] . Several studies have investigated the associations between pre-LT obesity and post-LT survival [11] [12] [13] . However, there is a paucity of data on how the frequently observed weight changes post LT impact patient and graft survival. Therefore, we sought to analyze the impact of post-LT weight and BMI changes on patient and graft survival using a large, national liver transplant database.
Patients and methods

Data source and cohort
We utilized data from the United Network for Organ Sharing (UNOS) Standard Transplant Analysis and Research file. Adults (≥18 years) were identified who had undergone primary LT between March 2002 and June 2009, had available data on pre-LT weight and height, and at least one recorded post-LT weight at 2 years from LT. We restricted our patient population by pre-LT BMI as well, as a previously published report from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Liver Transplant Database demonstrated that the presence of ascites results in misclassification of ∼ 11-20% of patients with large-volume ascites as being overweight or obese [12, 13] . Therefore, our study cohort included only LT recipients who had pre-LT BMI greater than 16 kg/m 2 and up to 25 kg/m 2 , as we did not have data pertaining to ascites volume in the UNOS dataset.
BMI calculations
Pre-LT BMI (kg/m 2 ) was calculated using the body weight (kg) obtained at the time of LT and the height (m) recorded at any time before LT. BMI was calculated using the following formula: [weight (kg)/height 2 (m 2 )]. Post-LT BMI was calculated using the post-LT recorded weight that was obtained temporally closest to 2 years from transplantation. The rationale behind selection of this 2-year time point for calculating post-LT BMI was based on the published investigation using the NIDDK Liver Transplant Database demonstrating stabilization in post-LT weight by the second year post LT [12] . The change in BMI between pre-LT and post-LT, defined as delta BMI, was calculated by subtracting the pre-LT BMI from the post-LT BMI.
To account for outliers in the UNOS data, particularly with respect to the recording of weight data, we excluded the following: recipients with pre-LT BMI less than 16 kg/m 2 (n = 240), as it would be unlikely for these adult patients to safely undergo LT with that degree of malnutrition; recipients with donors under the age of 10 years (n = 205), because of the low likelihood of such a young donor liver being suitable for an adult recipient; donors with recorded height less than 1.14 m (n = 7) or recorded weight less than 36 kg (n = 212), as these parameters correspond to the 50th and less than fifth percentile for height and weight, respectively, for a 10-year-old American girl; donors weighing more than 114 kg (n = 1482), as it is unlikely that such a large donor would be utilized.
Using delta BMI, we categorized LT recipients into three groups: (i) BMI gain, characterized by a gain of more than one BMI point from pre-LT to post-LT; (ii) BMI loss, characterized by a loss of more than one BMI point from pre-LT to post-LT; and (iii) BMI stable, characterized by a change of no more than one BMI point in either direction from pre-LT to post-LT. Substantial delta BMI was defined as a gain or loss of greater than three BMI points from pre-LT to post-LT, which correlates with a clinically notable 13% change in body weight for an average-sized adult.
Covariates
Recipient characteristics analyzed in this study included the following: age, sex, race (White vs. non-White), height (m), weight (kg), BMI (kg/m 2 ), Model For End-Stage Liver Disease (MELD) score at LT, primary liver disease diagnosis [hepatitis C (HCV), alcohol dependence, cryptogenic/nonalcoholic steatohepatitis, hepatitis B, or other], presence of hepatocellular carcinoma (HCC) or diabetes, need for dialysis or mechanical ventilation at the time of LT, hospitalization within 90 days before LT, and treatment for acute rejection within the first post-LT year.
Donor characteristics analyzed in this study included the following: age, sex, race (White vs. non-White), weight, height, BMI, cold ischemia time, donation after cardiovascular death, partial or split graft, and living donor graft.
Statistical analyses
Continuous data were summarized as mean ( SD) or median [interquartile range (IQR)], as appropriate. Statistical comparisons were made using Student's t-test, Wilcoxon's rank-sum test, or the χ 2 -test, as appropriate.
Unadjusted patient and graft 5-year survivals were calculated using the Kaplan-Meier method and compared using a log-rank test. Patient and graft survivals were calculated for the overall cohort and stratified by categories of post-LT delta BMI (BMI gain, BMI loss, and BMI stable). Survival analyses were also stratified by recipient pre-LT BMI category (BMI < 19, 19 to < 22, and 22-25 kg/m 2 ). Comparisons were made between recipients with and those without substantial delta BMI post LT. Patient survival and graft survival were calculated from the time of LT until death, graft failure, or the date of last follow-up.
Multivariable analyses to identify factors associated with patient and graft survival were carried out using Cox proportional hazard regression models, and data are presented as hazard ratios (HRs) with 95% confidence intervals (95% CIs). Covariates with P-values less than 0.10 in univariate analysis were entered into the multivariable model. Covariates with P-values less than 0.05 in multivariable analysis were considered statistically significant. All data analyses were carried out using SAS software, version 9.3 (SAS Institute, Cary, North Carolina, USA).
Results
Liver transplant cohort characteristics
We identified 31 254 adult primary LT recipients between March 2002 and June 2009. Of these, 9243 LT recipients had follow-up weight data recorded at 2 years post LT, and 2968 of these recipients had a pre-LT BMI that was greater than 16 kg/m 2 and up to 25 kg/m 2 . These 2968 LT recipients were included in our analyses, and their characteristics are shown in Table 1 . The mean age was 51 years (SD 11), and 63% (n = 1856) were men. The median pre-LT BMI was 22.8 kg/m 2 (IQR, 21.1-23.9), with hepatitis C (n = 871, 29.4%) being the leading etiology of liver disease. Twenty percent (n = 606) had a diagnosis of HCC pre LT. The median survival was not reached in the cohort, but the 8-year overall survival was 70% and the maximum post-LT follow-up time was 8 years.
Liver donor characteristics are shown in Table 1 . The mean age was 40 years (SD 18 years), and 53.3% (n = 1583) were men. The median donor BMI was 24.9 kg/m 2 (IQR, 22.0-28.2), and 147 donors (5%) donated after cardiac death.
Weight and BMI change post liver transplant
The median post-LT BMI significantly increased from 22.8 kg/m 2 (IQR, 21.1-23.9) pre LT to 23.8 kg/m 2 (IQR, 21.6-26.1), which is correlated to an increase of 1.4 kg/m 2 (P < 0.001). Of the LT recipients, 36% (n = 1071) met the BMI criteria for becoming either newly overweight (BMI ≥ 25 and < 30) or obese (BMI ≥ 30) at post-LT year 2, with 139 of these individuals being obese. BMI gain was demonstrated in 54% (n = 1612) of liver recipients, BMI loss in 20% (n = 581), and BMI stable in 26% (n = 775). Demographic comparisons of the recipients belonging to the three delta BMI categories are shown in Table 1 . The three groups were similar for most variables; however, LT recipients with BMI loss at 2 years post LT started with a higher pre-LT BMI [median 23.1 (IQR, 21.9-24.2)] compared with the other two groups (P < 0.001 for both). The median calculated MELD score at LT was higher among patients with BMI gain [18] [19] [20] [21] [22] [23] [24] ], compared with BMI loss [17] [18] [19] [20] [21] [22] [23] [24] , P = 0.005] and BMI stable [16] [17] [18] [19] [20] [21] [22] [23] , P < 0.001]. There was also a lower prevalence of HCC among patients with BMI gain (16.1%) compared with those with BMI loss (24.3%) or BMI stable (26.5%, P < 0.001 for both). Statistically significant differences were also seen in the following donor factors between the three delta BMI groups: donor weight (P = 0.004), donor BMI (P = 0.002), and cold ischemia time (P = 0.027).
Impact of pre-liver transplant BMI on survival
Five-year patient survival in the overall cohort was 85.9%, and the 5-year patient survival was similar when stratified by pre-LT BMI: 90.5% for BMI less than 19 kg/m 2 (n = 201), 84.8% for BMI 19 to less than 22 kg/m 2 (n = 903), and 85.9% for BMI 22-25 kg/m 2 (n = 1864; P > 0.10 for all comparisons; Fig. 1a ). The 5-year graft survival for the overall cohort was 84.5%, and the 5-year graft survivals stratified by pre-LT BMI were as follows: 90.5% for BMI less than 19 kg/m 2 , 83.4% for BMI 19 to less than 22 kg/m 2 , and 84.4% for BMI 22-25 kg/m 2 . (Fig. 1b ). Interestingly, LT recipients with pre-LT BMI less than 19 kg/m 2 had a greater graft survival compared with LT recipients with pre-LT BMI from 19 to less than 22 kg/m 2 , which was statistically significant by 8 years post LT (P = 0.032).
Impact of delta BMI on survival
Five-year patient and graft survivals stratified by delta BMI are shown in Fig. 2a and b, respectively. Patient survival was significantly better for recipients with BMI gain (90.1%) compared with recipients with either BMI loss (77.2%) or BMI stable (83.3%, P < 0.001 for both). Similarly, 5-year graft survival among recipients with BMI gain (89.4%) was significantly greater than graft survival among recipients with either BMI loss (74.3%) or BMI stable (82.0%, P < 0.001 for both).
We further evaluated 5-year patient and graft survivals with specific attention to recipients with substantial delta BMI, which are shown in Fig. 3a and b, respectively. The 5-year patient survivals were as follows: 89.7% for substantial BMI gain (>3 kg/m 2 ), 90.7% for BMI gain (>1 to 3 kg/m), 83.3% for BMI stable, 78.5% for BMI loss (>1 to 3 kg/m 2 ), and 74.5% for substantial BMI loss (>3 kg/m 2 ). The 5-year graft survivals were as follows: 89.3% for substantial BMI gain (>3 kg/m 2 ), 89.5% for BMI gain (>1 to 3 kg/m), 82.0% for BMI stable, 77.1% for BMI loss (< − 1 to − 3 kg/m 2 ), and 68.7% for substantial BMI loss (< − 3 kg/m 2 ). Recipients with substantial BMI loss had the lowest patient (74.5%) and graft (68.7%) survivals of the five groups analyzed. These changes were significantly lower than those in recipients with substantial BMI gain (P < 0.001 for patient and graft survivals). There was no significant decrease in 5-year patient survival between recipients with substantial BMI gain and recipients with lesser BMI gain (89.7 vs. 90.7%, respectively, P = 0.43). Although the 5-year graft survival was similar (89.3 vs. 89.5%) between these two groups (substantial BMI gain and lesser BMI gain), graft survival was actually higher at 8 years post LT for those recipients with substantial BMI gain (74.1%) compared with recipients with lesser BMI gain (59.8%, P = 0.041).
New-onset obesity post liver transplant
We compared recipients who developed new-onset obesity (BMI ≥ 30 kg/m 2 ; n = 139, 4.7%) by 2 years post LT with recipients who maintained stable BMI and found that recipients with new-onset obesity had significantly better 5-year patient (91.8 vs. 83.3%, P = 0.020) and graft (91.8 vs. 82.0%, P = 0.009) survivals ( Fig. 4) . Table 2 shows the characteristics of LT recipients who developed new-onset obesity by 2 years post LT compared with recipients whose BMI remained stable post LT. The prevalence of HCV as the primary liver disease etiology and the prevalence of HCC were lower in the new-onset obesity group compared with recipients with stable BMI (25.2 vs. 31.1% for HCV and 9.4 vs. 26.5% for HCC, P < 0.001 for both comparisons). Recipients with new-onset obesity also had a statistically significantly higher prevalence of pre-LT diabetes (25.2 vs. 16.7%, P = 0.016), were more likely to need dialysis pre LT (11.5 vs. 5.9%, P = 0.016), and had a higher calculated MELD score at the time of LT [22 (IQR 16-28) vs. 16 (IQR 11-23), P < 0.001].
Multivariable Cox regression analyses
Four patients had missing data on their pre-LT MELD score. Therefore, this analysis was based on 2964 patients. The median follow-up time for the overall cohort was 4.1 years (IQR 2.8-5.9). For patient survival, delta BMI (HR 0.89, 95% CI 0.86-0.92; P < 0.001, per 1 kg/m 2 change in BMI) was significantly and inversely associated with risk of death. Conversely, recipient and donor ages, recipient male sex, and receipt of a deceased donor liver were all statistically significantly associated with increased risk of death post LT (Table 3) . In a multivariable Cox regression analysis of graft survival, delta BMI (HR 0.89, 95% CI 0.86-0.91; P < 0.001, per 1 kg/m 2 change in BMI) was found to be significantly and inversely associated with the risk of graft loss. Conversely, recipient and donor ages, recipient male sex, and receipt of a deceased donor liver were found to be significantly associated with an increased risk of graft loss ( Table 4 ).
Cause of death
A total of 386 deaths occurred during the follow-up period. Of the patients who died, 106 (18.2%) belonged to the BMI loss group, 122 (15.7%) to the BMI stable group, and 158 (9.8%) to the BMI gain group. The most common identifiable causes of death included malignancy (n = 84), graft failure (n = 49), infection (n = 39), multiorgan failure (n = 31), and cardiovascular causes (n = 24). Of the deaths, 36 and 81 were classified as 'other' and 'unknown', respectively. Comparisons for cause of death stratified by delta BMI category were not undertaken because of the small number of events in each group.
Discussion
Obesity is a prevalent disorder in the US population that is associated with increased morbidity and mortality [2] . Similar to the general population, weight gain and propensity for obesity are commonly observed events among recipients of LTs, with post-LT weight gain having been demonstrated to stabilize in the majority of individuals by year 2 post LT [5] [6] [7] [8] [9] . Although the impact of pre-LT weight and BMI on post-LT survival has been extensively examined in the literature, the impact of weight and BMI changes occurring in the post-LT setting is not well understood. Using the UNOS database, our study demonstrated that weight gain (BMI gain) within the first 2 years post LT is common, occurring in 54% of We also demonstrated that LT recipients who gained weight within 2 years post LT had significantly greater patient and graft survivals compared with recipients who maintained stable BMI and those who experienced BMI loss. Further, LT recipients with new-onset obesity or who demonstrated substantial BMI gain also had greater 5-year patient and graft survivals compared with recipients who maintained stable BMI. Interestingly, LT recipients with normal pre-LT BMI who experienced weight loss had significantly reduced patient and graft survivals compared with other groups. And this detrimental effect was more pronounced among LT recipients with substantial weight loss. Multivariable analysis identified increasing BMI as an independent predictor of improved patient and graft survival. The baseline BMI used in this study limited the size of our cohort. However, it was chosen to mitigate the previously reported impact of pretransplant BMI, which included ascites weight that was unaccounted for, on posttransplant survival using the UNOS database [13] . Indeed, our analysis of 5-year patient and graft survivals stratified by baseline BMI did not reveal any such impact. Importantly, studies able to correct for ascites weight at LT have not reported a negative impact of pretransplant weight on post-transplant survival [11, 12] . Therefore, we believe that limiting our analysis to patients with a BMI of up to 25 kg/m 2 is warranted because we cannot correct for ascites weight in patients with high pretransplant BMI using the UNOS database. At the same time, we recognize that this analysis may include selection bias.
Data from the renal transplantation literature demonstrate an association between weight gain post transplant and features of the metabolic syndrome, as well as decreased patient and graft survival [14] [15] [16] [17] [18] . We hypothesized that similar negative effects would be observed in a post-LT cohort experiencing weight gain. However, our data demonstrate that weight gain, even substantial weight gain or new-onset obesity, at 2 years post LT is associated with better patient and graft survival compared with stable BMI. One potential explanation for the differences in the outcomes reported in the renal transplantation literature compared with the results of our investigation may be that baseline pretransplant comorbidities that contribute to patient mortality, such as cardiovascular and peripheral vascular diseases, are more prevalent among patients with end-stage renal disease undergoing renal transplantation compared with patients undergoing LT. We postulate that our LT BMI cohort had little ascites weight contributing to its pre-LT BMI and thus, early weight gain post LT may serve as a marker of better prognosis up to 5 years post LT. The analyzed BMI cohort likely included malnourished patients with cirrhosis who were still fit enough to undergo liver transplant surgery. Subsequently, these patients would have experienced an improvement in both malnourishment and liver failure, resulting in the observed increased BMI and better outcomes compared with the recipients who maintained a stable weight or who had post-LT weight loss. However, severely malnourished patients with normal BMI were likely few in this cohort, as these patients were ultimately deemed of sufficient health to undergo surgery by their transplant teams and had robust enough health to survive at least 2 years post LT. The impact of post-LT weight gain, especially substantial weight gain, on long-term (>5 years) patient and graft survivals is still not known. Furthermore, the impact of weight gain on pre-LT overweight or obese recipients, after accounting for ascites weight, is also not known. The negative effects of excessive weight and obesity on morbidity and mortality typically take years or decades to manifest in the general population, and the same phenomenon may be true in this LT cohort.
Our study also demonstrated that weight loss is associated with significantly reduced patient and graft survival. A large study of renal transplantation recipients in Australia and New Zealand identified post-transplant weight loss of more than 5% to be a marker of increased risk of death [14] . We do note that the BMI loss group in our study had a greater prevalence of HCV and HCC diagnoses compared with LT recipients who experienced BMI gain post LT. However, multivariate analyses failed to identify diagnoses of HCV or HCC as being independently associated with reduced patient or graft survival. A recent study of the Scientific Registry of Transplant Recipients dataset revealed that HCV infection was associated with an increased risk for diabetes after LT [19] . We suspect that HCV infection may also be associated with weight gain, as diabetes is frequently associated with the metabolic syndrome and obesity. However, posttransplant weight changes were not analyzed in the study by Younossi and colleagues, making our study novel. The BMI loss group, with a higher prevalence of HCV, compared with the BMI gain group, likely represents a subset of patients who experience more severe HCV recurrence with resultant graft cirrhosis and failure within the first 5 years after transplant. Similarly, the increased prevalence of HCC in the BMI loss group relative to the BMI gain group also suggests a difference in tumor characteristics including HCC recurrence between these two groups. Malignancy, which included liver and nonliver tumors, graft failure, and infections were the most common causes of death in this cohort. These would be common causes of death among nonoverweight recipients experiencing weight loss after LT and could explain our findings.
Our study has limitations that warrant further mention. Weight is not static. Previously published data using the NIDDK liver transplant database demonstrated that BMI post LT stabilizes by year 2 post LT [6] . Therefore, we specifically included cases that had documented BMI at year 2 and analyzed their survival with the assumption that the BMI would not change significantly after year 2. We also selected patients with a pre-LT BMI of up to 25 kg/m 2 (but > 16 kg/m 2 ), in an effort to account for large-volume ascites, given the published data demonstrating that the negative associations between elevated pre-LT BMI and risk of death and graft failure post LT are confounded by the presence of large-volume ascites [12] . However, as UNOS data do not include an accurate assessment of ascites volume, we used elevated BMI pre LT above the normal BMI threshold (25 kg/m 2 ) as a surrogate marker of ascites, with the presumption that the included patients (BMI ≤25 kg/m 2 ) did not have large volumes of ascites. We made this decision accepting the possibility of some degree of misclassification. Our survival analyses stratified by pre-LT BMI showed no impact on post-LT patient or graft survival, suggesting that we selected a group of patients whose pre-LT weight, which may have also included a few individuals with otherwise unaccounted for ascites (i.e. misclassified), did not impact post-LT patient and graft survivals. Another surrogate marker for more severe liver disease, such as the albumin to globulin ratio, would allow us to classify patients with less or more severe liver disease. However, the albumin to globulin ratio and other surrogate serologic studies cannot accurately predict which patients have or do not have ascites. Furthermore, the UNOS dataset we used did not collect globulin data from the transplant centers. We note that nonalcoholic steatohepatitis as the primary liver diagnosis was uncommon (5.9%) in this cohort, which likely reflects the selection of patients with normal pre-LT BMI. Finally, we recognize that post-transplant immunosuppressive medications can impact weight change, as well as the risk for new-onset diabetes mellitus [20] . Corticosteroid use likely plays a large role in posttransplant weight changes, as they remain a common post-transplant treatment. Newer immunosuppressive medications allow most centers to quickly taper off of corticosteroids such that most patients are no longer using corticosteroids within the first 6 months of transplant. Yet some post-transplant conditions, such as acute graft rejection, require reinstitution of these medications at very high doses. Hence, many times, corticosteroid use fluctuates over the course of the first 2 years after transplant, making statistical comparisons between steroid usage and weight changes very difficult. Furthermore, the UNOS dataset does not collect this granular level of information on dosage and duration of corticosteroid use. We could not assess the impact of immunosuppressive medications, particularly corticosteroids, on post-LT weight change because of the lack of granular data on corticosteroid use.
Conclusion
Weight gain post LT among nonoverweight/nonobese recipients is not only common, but is also associated with excellent patient and graft survival. Within 8 years post LT, there were no detrimental effects on survival from weight gain. We also demonstrated that LT recipients with weight loss within the first 2 years post LT, particularly substantial weight loss, have a significantly increased risk of death and graft loss. These data suggest that recipients with weight loss post LT require close monitoring for smoldering complications that may lead to poor post-LT outcomes. Although weight gain within the first 2 years post LT may be associated with favorable short-term prognoses, LT recipients should be discouraged from excessive weight gain until further research provides insight into the long-term impact of weight gain on patient and graft survival.
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